NCT05961410 (EPBSCH) is a Phase 2 clinical trial of Eltrombopag olamine in Lymphoma, sponsored by National Taiwan University Hospital.

Who is sponsoring NCT05961410?

NCT05961410 is sponsored by National Taiwan University Hospital.

What drugs are being tested in NCT05961410?

Interventions in NCT05961410: Eltrombopag olamine.

What condition does NCT05961410 study?

NCT05961410 studies Lymphoma, Peripheral Blood Stem Cell Transplantation.

Is NCT05961410 still recruiting?

NCT05961410 is currently recruiting now. Last updated 18 October 2024.

Last reviewed 2024-10-18 · How we verify

NCT05961410: EPBSCH

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Eltrombopag for Peripheral Blood Stem Cell Harvest

Recruiting now Phase 2 Last updated 18 October 2024

What this trial tests

Phase 2 trial testing Eltrombopag olamine in Lymphoma in 46 participants. Currently enrolling.

Timeline

15 August 2023

Primary endpoint
31 March 2025

1 March 2026

Quick facts

Lead sponsor	National Taiwan University Hospital
Phase	Phase 2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	46
Start date	15 August 2023
Primary completion	31 March 2025
Estimated completion	1 March 2026
Sites	1 location across Taiwan

Drugs / interventions tested

Eltrombopag olamine — full drug profile →

Conditions studied

Lymphoma — all drugs for Lymphoma →
Peripheral Blood Stem Cell Transplantation — all drugs for Peripheral Blood Stem Cell Transplantation →

Sponsor

National Taiwan University Hospital

Who can join

18 and older, any sex, with Lymphoma or Peripheral Blood Stem Cell Transplantation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this clinical trial is to explore the activity of eltrombopag in lymphoma patients receiving autologous hematopoietic stem cell harvest. The main questions it aims to answer are: * Determine the efficacy of adding eltrombopag during autologous hematopoietic stem cell mobilization and harvest. * Determine the pharmacokinetics and pharmacodynamics of serum eltrombopag concentration, circulating CD34+ cells during autologous hematopoietic stem cell mobilization. Participants will receiving additional eltrombopag during stem cell harvest procedure. The amount of harvested stem cells will be compared with historical group to see if eltrombopag could increase the amount of harvested stem cells.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

RNA m6A modification in ferroptosis: implications for advancing tumor immunotherapy.
Shi JX, Zhang ZC, Yin HZ, Piao XJ, et al · · 2024 · cited 29× · PMID 39342168 · DOI 10.1186/s12943-024-02132-6

Verify or expand the search:

Other recruiting trials for Lymphoma

Currently open trials in the same condition.

NCT07302347 — A Study of Pembrolizumab in Japanese Pediatric Participants With Solid Tumors or Lymphomas and Japanese Adult Participan · Phase 1, PHASE2 · recruiting
NCT07566377 — Cord Blood Transplantation in Children and Young Adults With Blood Cancer · Phase 2 · recruiting
NCT06856226 — Natural History Study to Determine Drug Metabolism Phenotype and Appropriate Germline Source DNA in Patients Undergoing · recruiting
NCT07226934 — An AI-Generated, Personalized Question Prompt List Intervention for Patients With Hematologic Cancers · NA · recruiting
NCT07138547 — GSL Synthetase Inhibitor Eliglustat Combined With CD30 Target Immunotherapy for the Treatment of of CD30+ Lymphoma · Phase 1, PHASE2 · recruiting

Other National Taiwan University Hospital trials

Trials by the same sponsor.

NCT06936917 — Timing for Computed Tomography and Post-Resuscitation Care on Short-Term Outcomes in Out-of-Hospital Cardiac Arrest · not yet recruiting
NCT05396222 — A Prospective Study of the Safety and Efficacy of 3D-printed Non-rigid Biomimetic Implant in Cervical and Thoracolumbar · NA · not yet recruiting
NCT07532356 — Integrating Tumor Genomics and Urinary Exosomal Proteomics to Establish a Multi-Layer Biomarker Framework for Early Risk · not yet recruiting
NCT07317310 — The NTU JO-SMART Study · NA · not yet recruiting
NCT07382024 — Tirzepatide to Reduce rEcurrence And Burden After Ablation of Atrial Fibrillation · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05961410 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by National Taiwan University Hospital
Last refreshed: 18 October 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05961410.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing